Cancel
About Dan Lin-Arlow
Dan Lin-Arlow is the Chief Scientific Officer who played a pivotal role as his company prepared for the commercial launch of its innovative rapid enzymatic synthesis technology for clonal genes and gene fragments.
Known information
Dan Lin-Arlow serves as the Chief Scientific Officer at a biotechnology firm, transitioning into this role as the company geared up for a full commercial launch of its groundbreaking rapid enzymatic synthesis technology. This technology is designed to enhance the production of complex clonal genes and gene fragments. Lin-Arlow has been an active participant in the scientific community, presenting ‘Reshaping Biology with the Power of Enzymatic DNA Synthesis’ during a Spotlight session at the Global Synthetic Biology Conference. Additionally, he engaged in a Breakout session at the same conference, where he discussed the future of DNA synthesis alongside other industry thought leaders.
About Ansa Biotechnologies
Ansa Biotechnologies, based in Emeryville, CA, specializes in enzyme-based DNA synthesis, focusing on sequences that are challenging to produce with existing methods. The company, part of the Y Combinator W20 batch, has raised $68 million in Series A financing to expand its innovative DNA synthesis technology.
Report inaccurate information